Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corvus Pharma Com (NQ: CRVS ) 5.200 +0.020 (+0.39%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 354,588 Open 5.160 Bid (Size) 5.000 (1) Ask (Size) 5.200 (17) Prev. Close 5.180 Today's Range 5.070 - 5.410 52wk Range 1.050 - 6.150 Shares Outstanding 62,551,281 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session September 18, 2024 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire Performance YTD +195.45% +195.45% 1 Month +25.91% +25.91% 3 Month +190.50% +190.50% 6 Month +190.50% +190.50% 1 Year +253.74% +253.74% More News Read More Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday September 16, 2024 Via Benzinga Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket August 07, 2024 Via Benzinga Earnings Outlook For Corvus Pharma March 18, 2024 Via Benzinga Preview: Corvus Pharma's Earnings November 06, 2023 Via Benzinga The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now May 31, 2024 Via InvestorPlace CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024 May 06, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's After-Market Session April 09, 2024 Via Benzinga CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023 March 19, 2024 Via InvestorPlace Earnings Scheduled For March 19, 2024 March 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session February 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session February 08, 2024 Via Benzinga Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell January 23, 2024 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket December 11, 2023 Via Benzinga Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial December 09, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results November 07, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition November 02, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases November 01, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 October 31, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session September 06, 2023 Via Benzinga Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session September 07, 2023 Via Benzinga Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA September 06, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer August 18, 2023 Via Benzinga Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results August 08, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
